Liver Transplant in Patients with Primary Sclerosing Cholangitis: Long-Term Experience of a Single Center

• Published in: Experimental and clinical transplantation Vol. 16; no. 4; pp. 434 - 438
• Main Authors: Astarcioglu, Ibrahim, Egeli, Tufan, Unek, Tarkan, Akarsu, Mesut, Sagol, Ozgul, Obuz, Funda, Ozbilgin, Mucahit, Aysal Agalar, Anil, Ağalar, Cihan
• Format: Journal Article
• Language: English
• Published: Turkey Başkent Üniversitesi 01.08.2018
• Subjects: Tıp; Ankara; Türkiye; Bile duct disease; Survival; End-stage liver disease; Fibrosis
• ISSN: 1304-0855; 2146-8427
• DOI: 10.6002/ect.2018.0159

Primary sclerosing cholangitis is a chronic inflammatory disease of the intrahepatic and extrahepatic bile ducts. More than half of the patients will face end-stage liver disease and require liver transplant. Here, we describe the long-term outcomes of liver transplant in patients with primary sclerosing cholangitis at our center. For this retrospective, observational study, we investigated all patients who underwent liver transplant for primary sclerosing cholangitis between January 2005 and June 2013 at the Dokuz Eylul University Hospital. Patient data were obtained from hospital records. Our inclusion criteria were patients over 18 years old and diagnosed with primary sclerosing cholangitis. Of 11 patients included the study, 6 (54.5%) were male and 5 (45.5%) were female. Mean age was 40.6 ± 11.0 years (range, 23-60 y). All patients had cirrhosis due to primary sclerosing cholangitis. With regard to Child-Turcot-Pugh classification, 2 patients (18.2%) were classified as having Child-Turcot-Pugh A cirrhosis, 7 patients (63.6%) were classified as having B cirrhosis, and 2 patients (18.2%) were classified as having C cirrhosis. Mean Modified End-Stage Liver Disease score was 17.5 ± 6.1 (range, 7-25). Cholangiocarcinoma was not detected in explant pathologic examinations. Primary sclerosing cholangitis recurrence developed in 2 patients (18.1%). Three patients (27.2%) died during the follow-up period. Liver transplant is a good therapeutic option for primary sclerosing cholangitis with satisfactory long-term outcomes. Liver transplant should be reserved for patients with end-stage liver disease and other conditions that significantly impair quality of life.